手机验证
/
PLC-PRF-5; PLC PRF 5; PLC/PRF5; PLCPRF5; PLC-8024; PLC8024; PLC; Alexander cells; Alexander; Primary Liver Carcinoma/Poliomyelitis Research Foundation/5
/
充足
/
/
/
/
/
肝癌;亚力山大细胞
人肝癌亚力山大细胞
人
/
上皮细胞样
/
肝癌;亚力山大细胞
复苏发货或干冰冷冻发货
/
贴壁
1 x 10^6 cells/vial/T25
细胞名称:PLC/PRF/5人肝癌亚力山大细胞(STR鉴定正确)
产品货号:C1027
培养条件:MEM+10%FBS(货号:M0301)
生长特性:贴壁
细胞形态:上皮样
产品规格:1 x 10^6 cells/vial/T25
产品货号 | 细胞名称 | 中文名称 | 生长特性 | 细胞形态 | 产品规格 |
C1010 | HCCLM3 | 人肝癌细胞( 高转) | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1011 | Hep 3B2.1-7 | 人肝癌细胞 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1013 | HuH-7 | 人肝癌细胞 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1110 | Hep G2 | 人肝癌细胞 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1030 | BEL-7404 | 人肝癌细胞 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1035 | MHCC97-L | 人肝癌细胞( 低转) | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1072 | HCCC-9810 | 人胆管细胞型 肝癌细胞 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1093 | Li-7 | 人肝癌细胞 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1117 | MHCC97-H | 人肝癌细胞( 高转) | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1193 | SK-HEP-1 | 人肝癌细胞 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
C1322 | SMMC7721/DDP | 人肝癌顺铂耐 药株 | 贴壁 | 上皮样 | 1 x 10^6 cells/vial/T25 |
用户须知:
1、关于货期:除复苏细胞外,承诺货期1周内到(节假日顺延),大多数产品1-3天内发货。细胞产品因需要复苏后进行1-2代传代调整后等待细胞长满,期间进行微生物检测,货期1、2周左右。
2、关于订购:为了保证您的权益,下单前务必联系我司客户服务热线(021-55150076)。
安全性:
所有肿瘤和病毒转染的细胞均视为有潜在的生物危害性,必须在二级生物安全台内操作,并请注意防护。
公司简介:
WheLab 是一家位于上海的高新技术公司,专注于细胞培养和分子生物学资源开发,服务于各大科研院校、医院和医药企业。 公司拥有先进的分子实验室、细胞培养间、液氮罐,收藏了1000+ 种细胞系,来源于ATCC细胞,DSMZ细胞,JCRB细胞,RIKEN细胞,ScienCell细胞等机构。同时包含自主研发建系的各类示踪细胞、耐药株、基因敲除细胞等。实验室可配制基础实验所需的常规试剂,实验室管理规范,细胞株均有STR鉴定和支原体检测,质量保证! 我们拥有国内、美国海归等丰富经验与专业技术的精英团队,秉承“专业、诚信、可靠”为公司宗旨,以合理的价格,完善的服务,提供可靠的产品,为广大客户提供完整的生物细胞技术解决方案。
如果您需要进一步的信息和服务,欢迎联系我们。
联系人:童小姐
电话:15921090068(微信同号)
:2306932016
:021-55150076
官网:https://whelab.com
公司邮箱:info@whelab.com
技术邮箱:tech@whelab.com
地址:上海宝山区呼兰西路129号8号楼4层
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
PubMed=63998
Alexander J.J., Bey E.M., Geddes E.W., Lecatsas G.
Establishment of a continuously growing cell line from primary carcinoma of the liver.
S. Afr. Med. J. 50:2124-2128(1976)
PubMed=184551
Alexander J.J., Bey E.M., Whitcutt J.M., Gear J.H.S.
Adaptation of cells derived from human malignant tumours to growth in vitro.
S. Afr. J. Med. Sci. 41:89-98(1976)
PubMed=187208; DOI=10.1038/bjc.1976.205
MacNab G.M., Alexander J.J., Lecatsas G., Bey E.M., Urbanowicz J.M.
Hepatitis B surface antigen produced by a human hepatoma cell line.
Br. J. Cancer 34:509-515(1976)
PubMed=6160110; DOI=10.1128/IAI.30.2.607-611.1980
Daemer R.J., Feinstone S.M., Alexander J.J., Tully J.G., London W.T., Wong D.C., Purcell R.H.
PLC/PRF/5 (Alexander) hepatoma cell line: further characterization and studies of infectivity.
Infect. Immun. 30:607-611(1980)
PubMed=6248960; DOI=10.1126/science.6248960
Knowles B.B., Howe C.C., Aden D.P.
Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen.
Science 209:497-499(1980)
PubMed=6268737; DOI=10.1099/0022-1317-53-1-105
Oefinger P.E., Bronson D.L., Dreesman G.R.
Induction of hepatitis B surface antigen in human hepatoma-derived cell lines.
J. Gen. Virol. 53:105-113(1981)
PubMed=6275024; DOI=10.1099/0022-1317-57-1-95
Koshy R., Maupas P., Muller R., Hofschneider P.H.
Detection of hepatitis B virus-specific DNA in the genomes of human hepatocellular carcinoma and liver cirrhosis tissues.
J. Gen. Virol. 57:95-102(1981)
PubMed=6288577; DOI=10.1002/ijc.2910300106
Simon D., Aden D.P., Knowles B.B.
Chromosomes of human hepatoma cell lines.
Int. J. Cancer 30:27-33(1982)
PubMed=6889516; DOI=10.1016/0277-5379(82)90010-4
Sattler F.R., Paolucci S., Kreider J.W., Ladda R.L.
A human hepatoma cell line (PCL/PRF/5) produces lung metastases and secretes HBsAg in nude mice.
Eur. J. Cancer Clin. Oncol. 18:381-389(1982)
PubMed=6225510; DOI=10.1007/BF00199161
Keong A., Rabson A.R.
Supernatant derived from a human hepatocellular carcinoma cell line (PLC/PRF/5) activates a population of T-suppressor cells.
Cancer Immunol. Immunother. 15:178-182(1983)
PubMed=6555060; DOI=10.1007/BF00199162
Keong A., Herman J., Rabson A.R.
Supernatant derived from a human hepatocellular carcinoma cell line (PLC/PRF/5) depresses natural killer (NK) cell activity.
Cancer Immunol. Immunother. 15:183-187(1983)
PubMed=2414854
Aspinall S., Alexander J.J.
Hepatitis B virus gene expression in two cell lines, one derived from a natural human infection, the other experimentally infected in vitro.
S. Afr. Med. J. 68:751-754(1985)
PubMed=2992761; DOI=10.1016/0165-4608(85)90033-0
Pinto M.R., Bey E., Bernstein R.
The PLC/PRF/5 human hepatoma cell line. I. Reevaluation of the karyotype.
Cancer Genet. Cytogenet. 18:11-18(1985)
PubMed=2992762; DOI=10.1016/0165-4608(85)90034-2
Bowcock A.M., Pinto M.R., Bey E., Kuyl J.M., Dusheiko G.M., Bernstein R.
The PLC/PRF/5 human hepatoma cell line. II. Chromosomal assignment of hepatitis B virus integration sites.
Cancer Genet. Cytogenet. 18:19-26(1985)
PubMed=3023526; DOI=10.1099/0022-1317-67-11-2315
Aspinall S., Alexander J., Bos P.
Comparative expression of hepatitis B virus antigens in several cell model systems.
J. Gen. Virol. 67:2315-2323(1986)
DOI=10.1007/978-4-431-68349-0_4
Alexander J.J.
Human hepatoma cell lines.
(In) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo (1987)
PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x
Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.J., Revillard J.-P.
Purification of alpha 1-microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with alpha 1-microglobulin synthesized by human hepatocytes.
Eur. J. Biochem. 165:699-704(1987)
PubMed=2542205; DOI=10.1111/j.1349-7006.1989.tb02290.x
Tsuda H., Hirohashi S., Shimosato Y., Ino Y., Yoshida T., Terada M.
Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma.
Jpn. J. Cancer Res. 80:196-199(1989)
PubMed=1661347; DOI=10.2302/kjm.40.139
Saito H., Morizane T., Watanabe T., Kagawa T., Miyaguchi S., Kumagai N., Tsuchimoto K., Tsuchiya M.
Proto-oncogene expression in three human hepatoma cell lines, HCC-M, HCC-T and PLC/PRF/5.
Keio J. Med. 40:139-145(1991)
PubMed=1317878; DOI=10.1016/0166-0934(92)90047-h
Grabow W.O.K., Puttergill D.L., Bosch A.
Propagation of adenovirus types 40 and 41 in the PLC/PRF/5 primary liver carcinoma cell line.
J. Virol. Methods 37:201-207(1992)
PubMed=8224613; DOI=10.1096/fasebj.7.14.8224613
Puisieux A., Galvin K., Troalen F., Bressac B., Marcais C., Galun E., Ponchel F., Yakicier C., Ji J.-W., Ozturk M.
Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines.
FASEB J. 7:1407-1413(1993)
PubMed=8389256; DOI=10.1093/carcin/14.5.987
Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T., Harris C.C.
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.
Carcinogenesis 14:987-992(1993)
PubMed=7874267; DOI=10.1007/BF02349278
Ikuta S., Itoh F., Hinoda Y., Toyota M., Makiguchi Y., Imai K., Yachi A.
Expression of cytoskeletal-associated protein tyrosine phosphatase PTPH1 mRNA in human hepatocellular carcinoma.
J. Gastroenterol. 29:727-732(1994)
PubMed=8050184; DOI=10.1111/j.1365-2249.1994.tb06089.x
Wadee A.A., Paterson A., Coplan K.A., Reddy S.G.
HLA expression in hepatocellular carcinoma cell lines.
Clin. Exp. Immunol. 97:328-333(1994)
PubMed=8835345; DOI=10.1002/(SICI)1096-9071(199602)48:2<133::AID-JMV3>3.0.CO;2-A
Tsuboi S., Nagamori S., Miyazaki M., Mihara K., Fukaya K.-I., Teruya K., Kosaka T., Tsuji T., Namba M.
Persistence of hepatitis C virus RNA in established human hepatocellular carcinoma cell lines.
J. Med. Virol. 48:133-140(1996)
DOI=10.11418/jtca1981.16.3_173
Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-I., Ohashi R., Namba M.
The p53 gene status and other cellular characteristics of human cell lines maintained in our laboratory.
Tissue Cult. Res. Commun. 16:173-178(1997)
PubMed=9023415; DOI=10.1006/cimm.1996.1062
Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Cell. Immunol. 175:101-110(1997)
PubMed=9178645; DOI=10.1006/cimm.1997.1108
Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M., Itoh K.
CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.
Cell. Immunol. 177:176-181(1997)
PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)
PubMed=9359923; DOI=10.18926/AMO/30789
Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-I., Ishioka C., Namba M.
Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory.
Acta Med. Okayama 51:261-265(1997)
PubMed=10523694; DOI=10.3892/or.6.6.1267
Gao C., Ohashi R., Pu H., Inoue Y., Tsuji T., Miyazaki M., Namba M.
Yeast functional assay of the p53 gene status in 11 cell lines and 26 surgical specimens of human hepatocellular carcinoma.
Oncol. Rep. 6:1267-1271(1999)
PubMed=11050057; DOI=10.1053/jhep.2000.19349
Wong N., Lai P., Pang E., Leung T.W.-T., Lau J.W.-L., Johnson P.J.
A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping.
Hepatology 32:1060-1068(2000)
PubMed=12029633; DOI=10.1053/jhep.2002.33683
Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M., Inazawa J.
TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.
Hepatology 35:1476-1484(2002)
PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234
Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Mol. Cancer Ther. 4:399-412(2005)
PubMed=20069059; DOI=10.1155/2010/437143
Srisomsap C., Sawangareetrakul P., Subhasitanont P., Chokchaichamnankit D., Chiablaem K., Bhudhisawasdi V., Wongkham S., Svasti J.
Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes.
J. Biomed. Biotechnol. 2010:437143.1-437143.18(2010)
PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)
PubMed=23505090; DOI=10.1002/hep.26402
Wang K., Lim H.Y., Shi S., Lee J., Deng S., Xie T., Zhu Z., Wang Y., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Hepatology 58:706-717(2013)
PubMed=23887712; DOI=10.1038/ncomms3218
Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nat. Commun. 4:2218.1-2218.7(2013)
PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)
PubMed=25574106; DOI=10.3748/wjg.v21.i1.311
Cevik D., Yildiz G., Ozturk M.
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
World J. Gastroenterol. 21:311-317(2015)
PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)
PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)
PubMed=29892436; DOI=10.1098/rsos.172472
Shioda S., Kasai F., Watanabe K., Kawakami K., Ohtani A., Iemura M., Ozawa M., Arakawa A., Hirayama N., Kawaguchi E., Tano T., Miyata S., Satoh M., Shimizu N., Kohara A.
Screening for 15 pathogenic viruses in human cell lines registered at the JCRB Cell Bank: characterization of in vitro human cells by viral infection.
R. Soc. Open Sci. 5:172472-172472(2018)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)
PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001
Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S., Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N., Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P., Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.
Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.
Gastroenterology 157:760-776(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)
PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001
Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J., Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y., Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J., Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H., Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X., Hui L.-J.
A pharmacogenomic landscape in human liver cancers.
Cancer Cell 36:179-193.e11(2019)
需要更多技术资料 索取更多技术资料
细胞售后说明.pdf 附 (下载 0 次)